Ken Griffin Selecta Biosciences Inc Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$0.62 - $0.85 $10,292 - $14,110	16,600 Added 8300.0%	16,800 $14,000
Q4 2023 Feb 14, 2024	SELL	$0.67 - $1.35 $10,385 - $20,925	-15,500 Reduced 98.73%	200 $0
Q3 2023 Nov 14, 2023	SELL	$1.02 - $1.23 $6,120 - $7,380	-6,000 Reduced 27.65%	15,700 $16,000
Q2 2023 Aug 14, 2023	SELL	$1.04 - $1.4 $17,368 - $23,380	-16,700 Reduced 43.49%	21,700 $24,000
Q1 2023 May 15, 2023	BUY	$1.15 - $1.89 $25,644 - $42,147	22,300 Added 138.51%	38,400 $53,000

Q4 2022 Feb 14, 2023	SELL	$0.96 - $1.6 $13,440 - $22,400	-14,000 Reduced 46.51%	16,100 $18,000
Q3 2022 Nov 14, 2022	BUY	$1.33 - $2.6 $22,743 - $44,460	17,100 Added 131.54%	30,100 $49,000

41.4M

16.8K

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.